Related references
Note: Only part of the references are listed.Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
Regina M. Myers et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage
Corinne Summers et al.
TRANSPLANTATION AND CELLULAR THERAPY (2022)
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Sanam Shahid et al.
TRANSPLANTATION AND CELLULAR THERAPY (2022)
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
Jordan Gauthier et al.
BLOOD (2021)
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Max S. Topp et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
Stephan Kadauke et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia
Cesar P. Marquez et al.
PEDIATRIC BLOOD & CANCER (2021)
Acute lymphoblastic leukemia: A population- based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017
Koji Sasaki et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children-a novel health disparity
Gordana Raca et al.
LEUKEMIA (2021)
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
Karlo Perica et al.
LEUKEMIA (2021)
Unlocking the potential of antibody-drug conjugates for cancer therapy
Joshua Z. Drago et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Immunogenicity of CAR T cells in cancer therapy
Dimitrios L. Wagner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
Shuangyou Liu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Olalekan O. Oluwole et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Li-Chung Tsao et al.
CANCER RESEARCH (2021)
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
Belen Blanco et al.
CLINICAL CANCER RESEARCH (2021)
Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Bijal D. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Regina M. Myers et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D. Shah et al.
LANCET (2021)
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Kathryn M. Cappell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Nora Liebers et al.
BLOOD ADVANCES (2021)
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Mohamed Abou-el-Enein et al.
BLOOD CANCER DISCOVERY (2021)
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson et al.
NATURE REVIEWS CANCER (2021)
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma
Kirk E. Cahill et al.
LEUKEMIA & LYMPHOMA (2020)
CAR T-Cell Therapy: Clinical Outcomes, Patient Selection and Financial Metrics with Tisagenlecleucel and Axicabtagene Ciloleucel, a Single Center Experience
Nathan Denlinger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro
Paulina Horvei et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
CAR T-cell product performance in haematological malignancies before and after marketing authorisation
Magdi Elsallab et al.
LANCET ONCOLOGY (2020)
Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy
Diane Libert et al.
LEUKEMIA (2020)
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Jennifer N. Brudno et al.
NATURE MEDICINE (2020)
Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma
Christopher M. Wright et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Hanren Dai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Pierre Sesques et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
How I treat relapsed acute lymphoblastic leukemia in the pediatric population
Stephen P. Hunger et al.
BLOOD (2020)
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Chelsea C. Pinnix et al.
BLOOD ADVANCES (2020)
Bilateral retinal detachment after chimeric antigen receptor T-cell therapy
Christopher C. Denton et al.
BLOOD ADVANCES (2020)
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
Bachar Samra et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas
P. Connor Johnson et al.
LEUKEMIA & LYMPHOMA (2020)
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Kathryn M. Cappell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
TO THE EDITOR: CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy COMMENT
Bicky Thapa et al.
BLOOD ADVANCES (2020)
Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
Sattva S. Neelapu et al.
BLOOD (2020)
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Rui-Xue Huang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
Nitin Jain et al.
BLOOD ADVANCES (2020)
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Kris M. Mahadeo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells
Alexandre V. Hirayama et al.
BLOOD (2019)
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Philipp Karschnia et al.
BLOOD (2019)
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis
Emma J. M. Grigor et al.
TRANSFUSION MEDICINE REVIEWS (2019)
Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: Reconciling biological concepts and clinical issues
Jeremie Gaudichon et al.
BLOOD REVIEWS (2019)
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
Ankit J. Kansagra et al.
BONE MARROW TRANSPLANTATION (2019)
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Jing Pan et al.
LEUKEMIA (2019)
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
Matthew J. Frigault et al.
BLOOD (2019)
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
Sandhya R. Panch et al.
MOLECULAR THERAPY (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
Yaqing Cao et al.
FRONTIERS IN ONCOLOGY (2019)
A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
Sunita Dwivedy Nasta et al.
BLOOD (2019)
CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial
Ann-Marie E. Broske et al.
BLOOD (2019)
Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Caspian Oliai et al.
BLOOD (2019)
Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel
Ajeet Gajra et al.
BLOOD (2019)
Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience
Jerome Paillassa et al.
BLOOD (2019)
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
Charalambos Andreadis et al.
BLOOD (2019)
A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331
Patrick A. Brown et al.
BLOOD (2019)
A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Peter A. Riedell et al.
BLOOD (2019)
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
Rebecca A. Gardner et al.
BLOOD (2019)
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
N. Nora Bennani et al.
BLOOD (2019)
Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory ( R/R) Large B Cell Lymphomas
Jeremy S. Abramson et al.
BLOOD (2019)
Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Michael D. Jain et al.
BLOOD (2019)
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Stephen J. Schuster et al.
BLOOD (2019)
Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Reith R. Sarkar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pharmacologic control of CAR-T cell function using dasatinib
Evan W. Weber et al.
BLOOD ADVANCES (2019)
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy
Vinodh Pillai et al.
BLOOD ADVANCES (2019)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
Inmaculada Hernandez et al.
JAMA ONCOLOGY (2018)
Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia
Elad Jacoby et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G. Majzner et al.
CANCER DISCOVERY (2018)
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
Loretta J. Nastoupil et al.
BLOOD (2018)
High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada
Sumit Gupta et al.
BLOOD (2018)
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
Caron A. Jacobson et al.
BLOOD (2018)
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy
Joshua A. Hill et al.
BLOOD (2018)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Autologous lymphapheresis for the production of chimeric antigen receptor T cells
Elizabeth S. Allen et al.
TRANSFUSION (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Building blocks for institutional preparation of CTL019 delivery
Joseph McGuirk et al.
CYTOTHERAPY (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells
Franklin K. Fuh et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
CAR-T Cell Therapy for Lymphoma
Carlos A. Ramos et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
CAR-T Cell Therapies From the Transfusion Medicine Perspective
Andrew Fesnak et al.
TRANSFUSION MEDICINE REVIEWS (2016)
The Cell Killing Mechanisms of Hydroxyurea
Amanpreet Singh et al.
GENES (2016)
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Soranobu Ninomiya et al.
BLOOD (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Opportunities and challenges of radiotherapy for treating cancer
Doerthe Schaue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia
Cameron J. Turtle et al.
BLOOD (2015)
Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia: Clinical Facts and Fiction
Kjeld Schmiegelow et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Diffuse large B-cell lymphoma
Maurizio Martelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Asparaginases: A Successful Class of Drugs Against Leukemias and Lymphomas
Vassilios I. Avramis
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2011)
Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells
Claudia Wrzesinski et al.
JOURNAL OF IMMUNOTHERAPY (2010)
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells
A. Takeshita et al.
LEUKEMIA (2009)
Cyclophosphamide and cancer: golden anniversary
Ashkan Emadi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Targeting DNA topoisomerase II in cancer chemotherapy
John L. Nitiss
NATURE REVIEWS CANCER (2009)
Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells
Jie Cai et al.
CANCER RESEARCH (2008)
Effects of Dasatinib on Src Kinase Activity and Downstream Intracellular Signaling in Primitive Chronic Myelogenous Leukemia Hematopoietic Cells
Heiko Konig et al.
CANCER RESEARCH (2008)
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
MSK Sutherland et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
JM Rowe et al.
BLOOD (2005)
Timeline - Chemotherapy and the war on cancer
BA Chabner et al.
NATURE REVIEWS CANCER (2005)
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
R LeBlanc et al.
BLOOD (2004)
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
H Kantarjian et al.
CANCER (2004)
The biology and therapy of adult acute lymphoblastic leukemia
S Faderl et al.
CANCER (2003)
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
A Löffler et al.
BLOOD (2000)
Share Paper
